Entrada Therapeutics, Inc.
TRDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 63.4% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 24.1% | -0.2% | – | – |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 31.1% | -5.2% | – | – |
| EPS Diluted | 1.68 | -0.2 | -2.79 | -1.6 |
| % Growth | 940% | 92.8% | -74.4% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |